Product Name: Human LAG3 / CD223 Antibody (Favezelimab, Research Use)
Catalog Number: NBR-0788
Target Name: LAG3 / CD223
Trade Name: Favezelimab
Antibody Drug Description: Favezelimab is an ongoing LAG-3 antibody developed by Merck, which can block the interaction between MHCII receptors and LAG-3, inhibit the up-regulation of LAG-3, and then restore the killing effect of T cells on tumor cells. Appearance: Transparent Liquid
Molecular Weight: ~150kDa
CAS：N/A
Solubility: Water; PBS, TBS Buffer etc.
Expression System: CHO Expressed
Isotype of Ab: Ab. Isotype - IgG

  Gene Name: LAG3
Synonyms: CD223
Target Description: Lymphocyte activation gene 3 protein: Inhibitory receptor on antigen activated T-cells. Delivers inhibitory signals upon binding to ligands, such as FGL1 (By similarity).
Ensembl:  ENSG00000089692
Uniprot: P18627